Long-Term Outcome of Transcatheter Subsegmental and Segmental Arterial Chemoemobolization Using Lipiodol for Hepatocellular Carcinoma

Journal Article · Fri Jun 15 00:00:00 EDT 2012 · Cardiovascular and Interventional Radiology

DOI:https://doi.org/10.1007/S00270-011-0224-9· OSTI ID:21608523

Takaki, Satoshi; Sakaguchi, Hiroshi; Anai, Hiroshi; Tanaka, Toshihiro; Yamamoto, Kiyosei; Morimoto, Kengo; Nishiofuku, Hideyuki; Inoue, Masayoshi; Sueyoshi, Satoru ^[1]; Nagata, Takeshi ^[2]; Hidaka, Teruyuki ^[1]; Uchida, Hideo ^[2]; Kichikawa, Kimihiko ^[1]

---

1. Nara Medical University, Department of Radiology (Japan)
2. Daiyukai General Hospital, Interventional Radiology Center (Japan)

Purpose: To clarify the efficacy of transcatheter hepatic sub-subsegmental, subsegmental, and segmental arterial chemoembolization using lipiodol (subseg/seg lip-TACE) for hepatocellular carcinoma (HCC), long-term outcomes of patients who had been treated using subseg/seg lip-TACE alone were retrospectively examined. Materials and Methods: Subjects comprised 199 patients with HCC (T1/2/{>=}3 = 30/108/61; Child-Pugh A/B/C = 115/52/32; Japan Integrated Staging [JIS] score {<=}1/2/{>=}3 = 88/64/47) who underwent subseg/seg lip-TACE using lipiodol mixed with an anticancer drug followed by injection of gelatin sponge particles. Each patient was followed-up every 3 months, and repeat subseg/seg lip-TACE and/or conventional lip-TACE was performed in cases showing recurrence. One-, 3-, 5-, 7-, and 10-year cumulative survival rates were calculated. Subgroup analyses were performed by stratifying the population according to T-factor, Child-Pugh classification, and JIS score. Results: Median duration of follow-up was 3.8 years (range 0.2 to 16.4). Median overall survival was 3.8 years. One-, 3-, 5-, 7- and 10-year survival rates were 91.5, 66.1, 38.8, 20.3, and 9.4% for all patients, and 95.5, 76.9, 51.9, 27.9 and 20.4% for patients with JIS {<=}1, respectively. Significant survival differences were found across two subgroups of staging systems (T2 vs. T3{<=} [P = 0.0012] and JIS score {<=}1 vs. 2 [P = 0.0036]). Conclusion: This study demonstrated that subseg/seg lip-TACE is a feasible treatment for obtaining prolonged survival in patients with localized HCC showing rich vasculature. Outcomes are influenced by both tumor stage and liver function, as seen in the best prolonged survival in patients with JIS score {<=}1.

• OSTI ID: 21608523
• Journal Information: Cardiovascular and Interventional Radiology, Vol. 35, Issue 3; Other Information: DOI: 10.1007/s00270-011-0224-9; Copyright (c) 2012 Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Country of input: International Atomic Energy Agency (IAEA); ISSN 0174-1551
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ANTINEOPLASTIC DRUGS
GELATIN
HEPATOMAS
INJECTION
LIPIODOL
LIVER
MATERIALS
ORAL CAVITY
PATIENTS
BODY
CARCINOMAS
COLLOIDS
CONTRAST MEDIA
DIGESTIVE SYSTEM
DISEASES
DISPERSIONS
DRUGS
GLANDS
INTAKE
NEOPLASMS
OILS
ORGANIC COMPOUNDS
ORGANIC HALOGEN COMPOUNDS
ORGANIC IODINE COMPOUNDS
ORGANS
OTHER ORGANIC COMPOUNDS
PROTEINS